These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34709816)

  • 41. 3D based generative PROTAC linker design with reinforcement learning.
    Li B; Ran T; Chen H
    Brief Bioinform; 2023 Sep; 24(5):. PubMed ID: 37670499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current strategies for the design of PROTAC linkers: a critical review.
    Troup RI; Fallan C; Baud MGJ
    Explor Target Antitumor Ther; 2020; 1(5):273-312. PubMed ID: 36046485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PROTAC derivatization of natural products for target identification and drug discovery: Design of evodiamine-based PROTACs as novel REXO4 degraders.
    Chen S; Bi K; Liang H; Wu Z; Huang M; Chen X; Dong G; Sheng C
    J Adv Res; 2024 Sep; 63():219-230. PubMed ID: 37913903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Native mass spectrometry and gas-phase fragmentation provide rapid and in-depth topological characterization of a PROTAC ternary complex.
    Song JH; Wagner ND; Yan J; Li J; Huang RY; Balog AJ; Newitt JA; Chen G; Gross ML
    Cell Chem Biol; 2021 Oct; 28(10):1528-1538.e4. PubMed ID: 34081921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ternary Complex-Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo-PROTACs.
    Diehl CJ; Salerno A; Ciulli A
    Angew Chem Int Ed Engl; 2024 Jun; 63(25):e202319456. PubMed ID: 38626385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterizing the Cooperative Effect of PROTAC Systems with End-Point Binding Free Energy Calculation.
    Xu K; Wang Z; Xiang S; Tang R; Deng Q; Ge J; Jiang Z; Yang K; Hou T; Sun H
    J Chem Inf Model; 2024 Oct; 64(19):7666-7678. PubMed ID: 39361611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 51. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accelerating PROTACs Discovery Through a Direct-to-Biology Platform Enabled by Modular Photoclick Chemistry.
    Yan KN; Nie YQ; Wang JY; Yin GL; Liu Q; Hu H; Sun X; Chen XH
    Adv Sci (Weinh); 2024 Jul; 11(26):e2400594. PubMed ID: 38689503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes.
    Zhang L; Riley-Gillis B; Vijay P; Shen Y
    Mol Cancer Ther; 2019 Jul; 18(7):1302-1311. PubMed ID: 31064868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation.
    Wurz RP; Rui H; Dellamaggiore K; Ghimire-Rijal S; Choi K; Smither K; Amegadzie A; Chen N; Li X; Banerjee A; Chen Q; Mohl D; Vaish A
    Nat Commun; 2023 Jul; 14(1):4177. PubMed ID: 37443112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
    Tamatam R; Shin D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.
    Yokoo H; Naganuma M; Oba M; Demizu Y
    Chem Biodivers; 2022 Nov; 19(11):e202200828. PubMed ID: 36124821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor.
    Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
    Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
    Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras.
    Li F; Hu Q; Zhou Y; Yang H; Bai F
    Brief Bioinform; 2024 Jul; 25(5):. PubMed ID: 39101502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.